SG11201900405XA - Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia - Google Patents
Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemiaInfo
- Publication number
- SG11201900405XA SG11201900405XA SG11201900405XA SG11201900405XA SG11201900405XA SG 11201900405X A SG11201900405X A SG 11201900405XA SG 11201900405X A SG11201900405X A SG 11201900405XA SG 11201900405X A SG11201900405X A SG 11201900405XA SG 11201900405X A SG11201900405X A SG 11201900405XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- alcalde
- ste
- california
- gout
- Prior art date
Links
- 201000005569 Gout Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 201000001431 Hyperuricemia Diseases 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102000002269 Cytochrome P-450 CYP2C9 Human genes 0.000 abstract 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 231100000304 hepatotoxicity Toxicity 0.000 abstract 1
- 230000007056 liver toxicity Effects 0.000 abstract 1
- 230000037353 metabolic pathway Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662363473P | 2016-07-18 | 2016-07-18 | |
| PCT/US2017/041763 WO2018017368A1 (en) | 2016-07-18 | 2017-07-12 | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900405XA true SG11201900405XA (en) | 2019-02-27 |
Family
ID=60992707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900405XA SG11201900405XA (en) | 2016-07-18 | 2017-07-12 | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US10239854B2 (ko) |
| EP (2) | EP3484862B1 (ko) |
| JP (3) | JP2019524747A (ko) |
| KR (1) | KR102610573B1 (ko) |
| CN (3) | CN109790135B (ko) |
| AU (1) | AU2017298142B2 (ko) |
| CA (1) | CA3030821A1 (ko) |
| DK (1) | DK3484862T3 (ko) |
| EA (1) | EA201990333A1 (ko) |
| ES (2) | ES2897968T3 (ko) |
| IL (1) | IL264268B (ko) |
| PL (1) | PL3484862T3 (ko) |
| PT (1) | PT3484862T (ko) |
| SG (1) | SG11201900405XA (ko) |
| WO (1) | WO2018017368A1 (ko) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6799895B2 (ja) | 2015-06-09 | 2020-12-16 | リンファクト−リンフォサイト アクティベイション テクノロジーズ エス．エー． | ＴＣＲγδ＋Ｔ細胞の生産方法 |
| WO2018017368A1 (en) | 2016-07-18 | 2018-01-25 | Arthrosi Therapeutics, Llc | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia |
| JP2022510303A (ja) * | 2018-12-06 | 2022-01-26 | アースローシ セラピューティクス，インク． | 痛風または高尿酸血症を処置または予防するための方法 |
| JP2022511800A (ja) * | 2018-12-06 | 2022-02-01 | アースローシ セラピューティクス，インク． | 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 |
| KR20220016105A (ko) * | 2019-05-14 | 2022-02-08 | 아쓰로시 테라퓨틱스, 인크. | 통풍 또는 고요산혈증을 치료하기 위한 화합물 |
| EP3983415A4 (en) * | 2019-06-17 | 2023-07-05 | Fochon Pharmaceuticals, Ltd. | HETEROCYCLIC DERIVATIVES AND USE THEREOF |
| IL298833A (en) * | 2020-06-10 | 2023-02-01 | Arthrosi Therapeutics Inc | Methods for treating or preventing chronic kidney disease |
| WO2022169974A1 (en) | 2021-02-05 | 2022-08-11 | Nexys Therapeutics, Inc. | Inhibitors of urat1 and pharmaceutical uses thereof |
| TW202330485A (zh) * | 2021-12-02 | 2023-08-01 | 美商安索治療公司 | 用於治療或預防痛風或高尿酸血症之化合物的結晶形式 |
| TW202334103A (zh) * | 2021-12-30 | 2023-09-01 | 美商安索治療公司 | 用於治療痛風或高尿酸血症之化合物之製備 |
| WO2023149549A1 (ja) * | 2022-02-03 | 2023-08-10 | 国立大学法人富山大学 | 新規医薬組成物 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1023985A (en) | 1911-05-29 | 1912-04-23 | Louis Emile Beaulieu | Fish-plate bolt. |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
| KR0182801B1 (ko) | 1991-04-16 | 1999-05-01 | 아만 히데아키 | 고체 분산체의 제조방법 |
| HU227530B1 (en) | 1991-11-22 | 2011-07-28 | Warner Chilcott Company | Delayed-release compositions containing risedronate and process for their production |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| CA2147283C (en) | 1992-10-16 | 2007-01-16 | Kouichi Nakamichi | Method of manufacturing wax matrices |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| KR19990014865A (ko) | 1995-05-17 | 1999-02-25 | 피터 이. 브래이브맨 | 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들 |
| DE19624292A1 (de) * | 1996-06-18 | 1998-01-02 | Merckle Gmbh | Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| EP1767531A4 (en) * | 2004-06-10 | 2011-01-05 | Torii Pharmaceutical Co Ltd | MEDICINAL COMPOSITIONS CONTAINING 6-HYDROXYBENZBROMARONE OR SALTS THEREOF |
| US20080305169A1 (en) * | 2006-05-26 | 2008-12-11 | Japan Tobacco Inc. | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds |
| EP2139848A1 (en) * | 2007-04-26 | 2010-01-06 | Auspex Pharmaceuticals, Inc. | Deuterium labelled ketamine |
| JP5325065B2 (ja) * | 2009-09-30 | 2013-10-23 | 株式会社富士薬品 | 新規フェノール誘導体 |
| GB2484298A (en) | 2010-10-05 | 2012-04-11 | Plexus Ocean Syst Ltd | Subsea wellhead with adjustable hanger forming an annular seal |
| JP5844376B2 (ja) * | 2010-10-06 | 2016-01-13 | ジェイファーマ株式会社 | 強力な尿酸トランスポーター阻害剤の開発：それらの尿酸排泄効果のために設計された化合物 |
| US20150031768A1 (en) | 2011-08-19 | 2015-01-29 | The Trustees Of Princeton University | C-halogen bond formation |
| US9962362B2 (en) | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| WO2014113407A2 (en) * | 2013-01-16 | 2014-07-24 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting eya tyrosine phosphatase |
| MX2015016494A (es) * | 2013-05-31 | 2016-11-18 | Takeda Pharmaceuticals Usa Inc | Métodos de tratamiento y composiciones con inhibidores de xantina oxidasa. |
| WO2015134467A1 (en) * | 2014-03-05 | 2015-09-11 | The Trustees Of Princeton University | Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks |
| EP3174877B1 (en) | 2014-07-31 | 2022-06-29 | Merck Patent GmbH | Indolizine derivatives which are applicable to neurodegenerative diseases |
| CN104262305B (zh) | 2014-09-16 | 2016-06-08 | 东北制药集团股份有限公司 | 一种苯溴马隆晶型a及其制备方法 |
| CN104311516B (zh) | 2014-09-16 | 2017-01-11 | 东北制药集团股份有限公司 | 一种苯溴马隆晶型b及其制备方法 |
| WO2018017368A1 (en) | 2016-07-18 | 2018-01-25 | Arthrosi Therapeutics, Llc | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia |
| JP2022511800A (ja) | 2018-12-06 | 2022-02-01 | アースローシ セラピューティクス，インク． | 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 |
| JP2022510303A (ja) | 2018-12-06 | 2022-01-26 | アースローシ セラピューティクス，インク． | 痛風または高尿酸血症を処置または予防するための方法 |
-
2017
- 2017-07-12 WO PCT/US2017/041763 patent/WO2018017368A1/en unknown
- 2017-07-12 EP EP17831578.4A patent/EP3484862B1/en active Active
- 2017-07-12 ES ES17831578T patent/ES2897968T3/es active Active
- 2017-07-12 KR KR1020197004544A patent/KR102610573B1/ko active IP Right Grant
- 2017-07-12 AU AU2017298142A patent/AU2017298142B2/en active Active
- 2017-07-12 PL PL17831578T patent/PL3484862T3/pl unknown
- 2017-07-12 CA CA3030821A patent/CA3030821A1/en active Pending
- 2017-07-12 EP EP21185425.2A patent/EP3957629B1/en active Active
- 2017-07-12 EA EA201990333A patent/EA201990333A1/ru unknown
- 2017-07-12 SG SG11201900405XA patent/SG11201900405XA/en unknown
- 2017-07-12 DK DK17831578.4T patent/DK3484862T3/da active
- 2017-07-12 CN CN201780057295.8A patent/CN109790135B/zh active Active
- 2017-07-12 CN CN202110361823.7A patent/CN113214198B/zh active Active
- 2017-07-12 IL IL264268A patent/IL264268B/en unknown
- 2017-07-12 PT PT178315784T patent/PT3484862T/pt unknown
- 2017-07-12 JP JP2019502791A patent/JP2019524747A/ja active Pending
- 2017-07-12 CN CN202211434030.4A patent/CN116332886A/zh active Pending
- 2017-07-12 ES ES21185425T patent/ES2964344T3/es active Active
-
2018
- 2018-10-04 US US16/151,641 patent/US10239854B2/en active Active
-
2019
- 2019-02-05 US US16/268,367 patent/US10508093B2/en active Active
- 2019-11-14 US US16/684,046 patent/US11236058B2/en active Active
-
2020
- 2020-01-30 JP JP2020014109A patent/JP7418227B2/ja active Active
-
2021
- 2021-12-21 US US17/558,370 patent/US20220112171A1/en not_active Abandoned
-
2022
- 2022-08-04 US US17/817,440 patent/US20220396558A1/en not_active Abandoned
- 2022-09-12 JP JP2022144720A patent/JP2022188052A/ja active Pending
-
2023
- 2023-03-23 US US18/189,024 patent/US20230227419A1/en not_active Abandoned
- 2023-11-13 US US18/507,999 patent/US20240116888A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201906885TA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808306PA (en) | Treatment of cancer with tg02 | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201408232RA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201408808WA (en) | Method and system for treatment of biological tissue | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors |